Abstract
Chronic obstructive pulmonary disease (COPD) is a common cause of morbidity and mortality. The term is heterogenous and encompasses a number of distinct but often overlapping phenotypes including chronic bronchitis, small airways obstruction, emphysema and in some individuals, a systemic component. Although there have been significant advances in understanding the pathophysiology of COPD, understanding of the role of the inflammation in the pathogenesis of the condition remains in its infancy. Indeed, cytokines that are known to orchestrate the inflammatory response in asthma and other inflammatory diseases are only beginning to be reported in COPD. In this review, we highlight the potential role of cytokines in the development of mucus hypersecretion observed in chronic bronchitis and the morphological changes observed in the small airways and airspaces contributing to the development of airflow limitation and respiratory failure respectively. We report evidence that exacerbations are linked to increased expression of pro-inflammatory cytokines and that the wasting and skeletal muscle dysfunction observed in some patients is most probably related to the presence of a systemic inflammatory response. In addition transgenic and gene therapy technology has been used to explore the temporal and co-ordinated role of cytokines in the development of COPD animal models. Enhanced understanding of the events involved in the pathogenesis of COPD will lead to the development of therapy with potential to modify the observed progressive decline in lung function and impact on the development of the illness.
Keywords: Cytokines, Pulmonary Disease, hypersecretion, gene therapy
Current Pharmaceutical Design
Title: Cytokines in the Pathogenesis of Chronic Obstructive Pulmonary Disease
Volume: 9 Issue: 1
Author(s): P. T. Reid and J.- M. Sallenave
Affiliation:
Keywords: Cytokines, Pulmonary Disease, hypersecretion, gene therapy
Abstract: Chronic obstructive pulmonary disease (COPD) is a common cause of morbidity and mortality. The term is heterogenous and encompasses a number of distinct but often overlapping phenotypes including chronic bronchitis, small airways obstruction, emphysema and in some individuals, a systemic component. Although there have been significant advances in understanding the pathophysiology of COPD, understanding of the role of the inflammation in the pathogenesis of the condition remains in its infancy. Indeed, cytokines that are known to orchestrate the inflammatory response in asthma and other inflammatory diseases are only beginning to be reported in COPD. In this review, we highlight the potential role of cytokines in the development of mucus hypersecretion observed in chronic bronchitis and the morphological changes observed in the small airways and airspaces contributing to the development of airflow limitation and respiratory failure respectively. We report evidence that exacerbations are linked to increased expression of pro-inflammatory cytokines and that the wasting and skeletal muscle dysfunction observed in some patients is most probably related to the presence of a systemic inflammatory response. In addition transgenic and gene therapy technology has been used to explore the temporal and co-ordinated role of cytokines in the development of COPD animal models. Enhanced understanding of the events involved in the pathogenesis of COPD will lead to the development of therapy with potential to modify the observed progressive decline in lung function and impact on the development of the illness.
Export Options
About this article
Cite this article as:
Reid T. P. and Sallenave M. J.-, Cytokines in the Pathogenesis of Chronic Obstructive Pulmonary Disease, Current Pharmaceutical Design 2003; 9 (1) . https://dx.doi.org/10.2174/1381612033392440
DOI https://dx.doi.org/10.2174/1381612033392440 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Biological Significance of Polymorphism in Legume Protease Inhibitors from the Bowman-Birk Family
Current Protein & Peptide Science Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Current Pharmaceutical Design Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews Acne in the Adult
Mini-Reviews in Medicinal Chemistry Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews (Discontinued) Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Current Psychopharmacology Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism The Proteins Interacting with Prmt5 in Medaka (Oryzias latipes) Identified by Yeast Two-Hybridization
Protein & Peptide Letters Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Reported Breastfeeding Rates in the Asia-Pacific Region
Current Pediatric Reviews Ureas: Applications in Drug Design
Current Medicinal Chemistry Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Dietary Intervention for Allergic Disease
Current Pharmaceutical Design Editorial: Premenstrual Syndrome and Dyspnea: Where is the Data?
Current Respiratory Medicine Reviews Animal Models for Human Asthma: The Perspective of a Clinician
Current Drug Targets Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Propranolol Safety Profile in Children
Current Drug Safety Meet The Guest Editor
Combinatorial Chemistry & High Throughput Screening Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design